OVERVIEW

CJC‑1295 (no DAC) + GHRP‑2 10 mg (Blend) is a research peptide combination often used in laboratory studies to investigate growth hormone (GH) axis modulation. CJC‑1295 (no DAC) is a synthetic analog of growth hormone‑releasing hormone (GHRH) that stimulates somatotroph cells in the anterior pituitary to release GH by activating the GHRH receptor. Without the drug affinity complex (DAC), this form has a shorter half‑life and promotes pulsatile GH release that more closely mimics natural secretion patterns, which can be useful for studies focused on endocrine feedback and hormone rhythm regulation. GHRP‑2 is part of a class of synthetic peptides that act on the growth hormone secretagogue receptor (GHS‑R1a), also known as the ghrelin receptor, to trigger additional GH pulses. When combined in a blend, these peptides are proposed to produce a synergistic increase in GH levels by engaging separate receptor pathways, amplifying overall GH output compared to either peptide alone in experimental models.

Despite scientific interest, this peptide blend remains strictly a research compound and is not approved for medical use by the U.S. Food and Drug Administration. Evidence for its effects comes largely from preclinical and early‑stage studies, and there is limited data from controlled clinical trials establishing safety, efficacy, or appropriate human dosing. Products sold online as peptide blends are often labeled for research use only, and their purity and quality can vary widely, posing risks of contamination or inconsistent dosing. Because of these uncertainties and the absence of regulatory oversight, self‑administration outside of controlled research settings is not recommended; anyone interested in growth hormone regulation or metabolic therapies should consult qualified healthcare professionals and rely on evidence‑based medical guidance.